Lanly Bioscience
Current position:
Business Introduction

Resources and data

Business Introduction


Cardiovascular and metabolic diseases (CVMD)

Business introduction of various disease research platforms of Sino-American Crown Bio:

Cardiovascular diseases

Rodent model Cardiovascular disease technology and resources, including continuous telemetry of blood pressure

The ZDSD multi-gene rat model possesses a physiologically functional leptin pathway and is an animal model of hypertension with high transformation ability


Rodent diabetes model and our research services including continuous blood glucose monitoring

FATZO polygenic mouse model with functional leptin pathway, is a rodent diabetes model with stronger transformation ability

ZDSD multi-gene rat model with a functional leptin pathway, is a rodent diabetes model with stronger transformation ability and can develop diabetic complications

Spontaneous diabetes, non-human primate (NHP) model, capable of reproducing human disease phenotypes, metabolic pathology and sensitivity to hypoglycemic drugs


Obese rodent model technology and resources, and our main experimental endpoints

FATZO polygenic mouse model with functional leptin pathway for obesity and metabolic syndrome research

The ZDSD multi-gene rat model has a functional leptin pathway and is a transformable obesity research model that can be used to evaluate anti-adipogenic compounds

Spontaneous and feed-induced NHP obesity models can be used for metabolic abnormalities research and treatment evaluation

Kidney disease

Rodent nephropathy models including genetically related, transformable and induced disease models

Genetically related polycystic kidney (PKD) disease models including jck and pcy mice and PCK rats

ZDSD polygenic rat model has a functional leptin pathway and can develop diabetic nephropathy

Safety/toxicology experiment

Sino-American Crown Bio also provides non-GLP toxicology and safety pharmacology experiments in rodents and non-human primates (NHP)



Sino-American Crown Bio provides a comprehensive in vivo immunotherapy translational medicine technology platform. The following business profiles can bring you detailed information about our various immuno-oncology services:

CAR-T cell therapy model

Use our PDX model or CD19-positive tumor cell line-derived xenograft model to evaluate CAR-T therapy in vivo preclinically

Humanized model

Evaluation of cell line-derived allograft models or PDX models in humanized mice, including immune memory response

The MiXeno™ model is characterized by mice with a transient human immune system and provides a simple humanization scheme beyond the complete reconstruction of the human immune system using stem cells

HuGEMM™ and HuCELL™, our unique platform for evaluating human-specific immunotherapy, this platform inoculates mouse tumors on immune-sound mice with humanized drug targets

Rat-derived drug effect and pharmacokinetic model

Homologous models, showing our continuously expanding collection of homologous models, FACS analysis, and standardized treatment results at immune checkpoints

MuScreen™ A large-scale staggered immunotherapy drug screening platform in vivo

MuPrime™-an allograft model of spontaneous tumors in mice (derived from transgenic mice/carcinogen induction models), inoculated into immune-sound mice.

Take the MuPrime mBR6004 model as an example to show up close our fully researched MuPrime model, including gene expression, immunohistochemistry, pharmacodynamic data, and immune cell tumor infiltration analysis.

Fusion model

Tumor gene fusion is very important for tumor targeted therapy. It can provide potential drug targets for some patients. Our current business profile is as follows:


RET gene fusion colorectal cancer PDX model, including the analysis of the efficacy of RET inhibitors and the development of acquired resistance models.

FGFR3-TACC3 gene fusion non-small cell lung cancer and brain tumor PDX models and bladder cancer cell line-derived allograft models related business profiles include various treatment data and the development of in vivo and in vitro drug resistance models.

PDX model

The key features of our PDX model are currently summarized in our HuPrime® business profile.

In vitro experiments

The detailed information of our 3D cell culture platform includes the use of PDX-derived tumor cells for 3D tumor growth experiments (3D TGA)

Scan the QR code to read on your phone

Contact Us

Time of issue:2021-03-22 16:58:53

Address:99 Mengxi Road, Shaxi Town, Taicang City, Jiangsu Province

Time of issue:2021-03-22 17:01:27

Lanly Bioscience
Scan code to browse

Time of issue:2021-03-22 16:00:55

Copyright:Lanly Bioscience Technology (Suzhou) Co., Ltd. | Copyright - 2021 All Rights Reserved.       苏ICP备2021010176号       Powered by

Time of issue:2021-03-22 16:01:26

©Lanly Bioscience Technology (Suzhou) Co., Ltd.
Powered by